Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Preliminary Results from BCG-Unresponsive NMIBC Treatment

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton May 16, 2022 10:04pm

187 Views

Post# 34688036

RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

No, the combo had a 6% higher CR rate at 12 months than the standalone.

ScienceFirst wrote: Combo produced less convincing data???

____________________

Eoganacht - (5/16/2022 8:37:01 PM)

Preliminary Results from BCG-Unresponsive NMIBC Treatment

Preliminary results for a phase 2 trial of CG0070 used in conjunction with Keytruda were announced today at the AUA meeting. In the first 22 patients 8 achieved a CR at 12 months (36%) and 6 achieved a durable response (27%). As a standalone treatment in previous phase 1 and 2 trials CG0070 achieved a 12 month CR rate of just under 30%. Results seem to be very close to those of the combined use of BCG and N-803 announced on Friday.

Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC